This is in line with other reports explaining that monoclonal antibodies inhibiting IL-17 signaling (secukinumab, brodalumab and ixekizumab) and newer IL-23 antagonists (guselkumab, tildrakizumab and risankizumab) may offer greater disease control in psoriasis by acting on the main cytokine pathways driving psoriatic disease (3). Here, IL17A is linked to psoriasis.